MedTrace Logo

Surefire Precision Infusion System Registry

NCT02967523 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 111

Last updated 2018-09-11

No results posted yet for this study

Summary

This project involves the collection and analysis of retrospective and prospective data on patients diagnosed with hepatocellular carcinoma (HCC) in which the Surefire Precision Infusion System was used/will used be to deliver transarterial chemoembolization with doxorubicin-eluting beads (DEB-TACE). The purpose is to compare tumor and medical response in a real-world setting as well as identify potential areas for future clinical research.

Conditions

Interventions

DEVICE

DEB-TACE with Surefire Precision Infusion System

Subjects have undergone/will undergo DEB-TACE using the Surefire Precision Infusion System.

Sponsors & Collaborators

  • Surefire Medical, Inc.

    lead INDUSTRY

Principal Investigators

  • Baljendra Kapoor, MD · The Cleveland Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2018-06-18
Completion
2018-06-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02967523 on ClinicalTrials.gov